CN Patent

CN1457256A — 滴眼液

Assigned to Santen Pharmaceutical Co Ltd · Expires 2003-11-19 · 22y expired

What this patent protects

本发明的目的是将难溶于水且易于被吸附在树脂类容器上的前列腺素衍生物和溶于水时易于分解的前列腺素衍生物配制在滴眼液中。通过向滴眼液中加入非离子性表面活性剂如聚山梨酯80或聚氧乙烯氢化蓖麻油60，改善了前列腺素衍生物在水中的溶解性并显著抑制了其在树脂类容器上的吸附。通过加入抗氧化剂如乙二胺四乙酸二钠或二丁基甲酚可显著抑制前列腺素衍生物的分解。

USPTO Abstract

本发明的目的是将难溶于水且易于被吸附在树脂类容器上的前列腺素衍生物和溶于水时易于分解的前列腺素衍生物配制在滴眼液中。通过向滴眼液中加入非离子性表面活性剂如聚山梨酯80或聚氧乙烯氢化蓖麻油60，改善了前列腺素衍生物在水中的溶解性并显著抑制了其在树脂类容器上的吸附。通过加入抗氧化剂如乙二胺四乙酸二钠或二丁基甲酚可显著抑制前列腺素衍生物的分解。

Drugs covered by this patent

Patent Metadata

Patent number: CN1457256A
Jurisdiction: CN
Classification: —
Expires: 2003-11-19
Drug substance claim: No
Drug product claim: No
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.